The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports [PDF]
, 2020 Milan Tomić
openalex +1 more source
5PSQ-019 Analysis of the use of idarucizumab in a tertiary hospital
Section 5: Patient safety and quality assurance, 2023 C. Rodríguez-Tenreiro Rodríguez +9 more
semanticscholar +1 more source
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of CardiologyWorking Group on Cardiovascular Pharmacotherapy and European Society of CardiologyWorking Group on Thrombosis [PDF]
, 2015 Agewall, Stefan +15 more
core +1 more source
P2906Evaluation of appropriate use and clinical outcomes of idarucizumab as antidote of dabigatran in daily clinical practice [PDF]
, 2018 Sake J. van der Wall +10 more
openalex +1 more source
Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program [PDF]
, 2019 John Fanikos +9 more
openalex +1 more source
Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal [PDF]
, 2016 core +1 more source
Research and Practice in Thrombosis and Haemostasis, 2023 S. van der Horst +5 more
semanticscholar +1 more source